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Figure S1. βCH3 → αNH region of the NOESY spectra (500 MHz, CD3CN) of peptides 2a (A) and 
3a (B). Sequential (i → i+1) and medium-range (i → i+2), diagnostic of the presence of a 310-
helical structure are visible in both spectra. 
Figure S2. Amide region of the NOESY spectrum (500 MHz, CD3CN) of 2a. Sequential 
αNH(i)→αNH(i+1) are assigned in the spectrum. 
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Figure S3. Amide region of the NOESY spectrum (500 MHz, CD3CN) of 3a. Sequential 
αNH(i)→αNH(i+1) are assigned in the spectrum. 
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Figure S4. Model of 2a with the -(Aib)4- helical segment in the left-handed screw sense. 
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Figure S5. 1H NMR spectra (500 MHz in CD3OD) of 2a before irradiation (blue line) and after 
irradiation at 254 nm for different times (30 min, green line and 1h, red line). 
Figure S6. 1H NMR spectra (500 MHz in CD3OD) of 2b before irradiation (blue line) and after 
irradiation at 254 nm for different times (30 min, green line and 1h, red line) (A). Details of the 1H 
NMR spectra showing the glycinamide signals (B) and the olefininic protons (C). 
A  B 
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Figure S7. (A) 1H NMR spectra (500 MHz in CD3CN) of 2c before irradiation (blue line) and after 
irradiation at 254 nm for 2h. (B) 1H NMR spectra (500 MHz in CDCl3) of 3c before irradiation 
(blue line) and after irradiation at 312 nm for 2h.  
A 
B 
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Figure S8. UV-Vis absorption spectra of 2c (blue line) and 3c (red line) in MeOH solution. 
Figure S9. CD spectra of 2f in MeOH before irradiation (blue line) and after irradiation (red line) at 
254 nm (0.2 mM).  
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Figure S10. βCH3 → αNH region of the NOESY spectra (400 MHz, CD3CN) of peptides 2c (A) 
and 3c (B). 
 
 
Figure S11. βCH3 → αNH region of the NOESY spectra (400 MHz, CD3CN) of peptides 2d (A) 
and 3d (B). 
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Figure S12. βCH3 → αNH region of the NOESY spectra (400 MHz, CD3CN) of peptides 2e (A) 
and 3e (B). NH → NH region of the NOESY spectra (400 MHz, CD3CN) of peptides 2e (C) and 3e 
(D,E). 
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General Methods 
High-Performance Liquid Chromatography. The HPLC measurements were performed using an 
Agilent 1200 apparatus (Palo Alto, CA), equipped with a UV detector at 226 nm and a column 
Agilent Extend-C18 (stationary phase). Eluants: A= 9:1 H2O/CH3CN, 0.05 % TFA; B= 1:9 
H2O/CH3CN, 0.05 % TFA. 
Nuclear Magnetic Resonance. 1H NMR and 2D-NMR spectra (DQF-COSY, TOCSY and NOESY 
experiments) were recorded at 25, 45 and 65 °C on a Bruker Avance 400, 500 or 600 MHz 
instruments. 1H and 13C spectra were referenced relative to the solvent residual peaks and chemical 
shifts (δ) reported in ppm downfield of tetramethylsilane (CDCl3 δ H: 7.26 ppm, δ C: 77.16 ppm; 
CD3OD δ H: 3.31 ppm, δ C 49.05 ppm, CD3CN δ H: 1.94 ppm, δ C: 118.26 ppm). The multiplicity 
of a signal is indicated as br, broad; s, singlet; d, doublet; t, triplet; m, multiplet. Where 1H NMR 
spectra were run in MeOD exchangeable protons (NH, OH) are reported only where observed. 
Mass Spectrometry. High-resolution (HR) mass spectra by electrospray ionization (ESI), collected 
in the positive mode, were performed on two different instruments: 
i) Perseptive Biosystem Mariner ESI-ToF5220 spectrometer (Foster City, CA);  
ii) Thermo Finnigan MAT95XP (data were recorded by staff at the University of Manchester and 
are accurate to ± 0.001Da). 
Circular Dichroism. CD measurements were carried using a Jasco J-715 spectropolarimeter at 
different temperatures (20, 40 and 60°C) and a thermostatic system to control the temperature of the 
sample. Fused quartz cells of 0.2-mm and 1-mm path length (Hellma, Müllheim, Germany) were 
used. The value are expressed in terms of []T, the total molar ellipticity (deg x cm2 x dmol-1). 
Fourier Transform-Infrared Spectroscopy. FT-IR absorption spectra were recorded with a ATi 
Perkin Elmer Spectrum RX1 FT-IR spectrometer. The ῡ maxima for the main absorption bands are 
given. 
Melting point. Mps were determined on a GallenKamp apparatus and are uncorrected. 
UV lamp. A handheld UV Lamp (mineralight lamp, Model UVG-54) with wavelength of 254 nm 
(6W) was used in the photoisomerization experiments. 
UV-Vis Absorption. The UV-Vis absorption spectra were recorded using a Shimadzu model UV-
2501 PC spectrophotometer. A 1-cm path length quartz cell was used. 
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Photoisomerization experiments 
The sample was dissolved in deuterated solvent (CD3CN) and placed in a quartz NMR tube (Norrell 
S-500-QTZ). The sealed NMR tube was directly irradiated under the UV lamp without protective 
filter at a distance of about 4 cm from the light bulb. The NMR spectra were recorded before and 
after different irradiation times. Typically, 1-2 h of irradiation were sufficient to achieve E to Z 
conversion in 80-95% yield (without decomposition according to NMR and HPLC analyses). 
Formation of byproducts (< 5%) was detected by NMR only after long irradiation times (>18 h). 
Diastereoselection experiments 
Reactions of 5(4H)oxazolones with H-D,L-Val-OMe were performed in CH3CN or CH2Cl2 at 
controlled temperature using a thermostatic oil bath (20, 35, 45 and 70 °C). 
The carboxylic acid (10a-b or 11a-b) (0.05 mmol) was suspended in 5 mL of the appropriate 
solvent and EDC∙HCl (0.06 mmol) was added, and the solution stirred for 10 min at r.t. The 
quantitative formation of the oxazolone (12a-b or 13a-b) was controlled by HPLC. 
Separately H-D,L-Val-OMe∙HCl (0.31 mmol) and DIPEA (0.31 mmol) were suspended in 1 mL of 
the appropriate solvent. 
In a typical experiment, the oxazolone solution (500 μL, 1 equiv.) and the racemate solution (125 
μL, 8 equiv.) were mixed and the resulting solution was maintained under stirring in a thermostatic 
oil bath. The reaction was monitored by HPLC, by following the disappearance of the oxazolone 
accompanied by the formation of the two diastereomeric products. The formation of the two 
resulting peptides 15a-d (Z isomer) can be quantified directly by HPLC. Whereas in the case of 
14a-d (E isomer), after the disappearance of the oxazolone reactant, the product mixture was 
irradiated at 254 nm and successively analyzed by HPLC. The independent preparation of each 
diastereomer was performed by reaction of the oxazolone with either D or L H-Val-OMe. 
 
 
X-Ray diffraction  
Crystals of 2a and 3c were grown by slow evaporation from CH3CN and MeOH solutions, 
respectively. X-Ray diffraction data were collected with a Gemini E four-circle kappa 
diffractometer (Agilent Technologies) equipped with a 92 mm EOS CCD detector, using graphite 
monochromated Cu K radiation ( = 1.54178 Å). Data collection and reduction were performed 
with the CrysAlisPro software (version 1.171.36.28, Agilent Technologies). A semi-empirical 
absorption correction based on the multi-scan technique using spherical harmonics, implemented in 
the SCALE3 ABSPACK scaling algorithm, was applied. For 3c, diffraction data were collected up 
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to theta = 51.48°, as the crystal did not diffract significantly beyond 1.0 Å resolution, in all 
probability as a result of the combination of the small crystal size (minimum dimension 0.05 mm) 
with the relatively large asymmetric unit (five independent molecules, shown in Figure S13, for a 
total of 135 non-H atoms). 
Both structures were solved by ab initio procedures of the SIR 2014 program,1 and refined by full-
matrix least-squares on F2, using all data, by application of the SHELXL-2014 program,2 with 
anisotropic displacement parameters for all of the non-H atoms. H-Atoms were calculated at 
idealized positions and refined using a riding model. In the refinement of 3c, restraints were applied 
to the anisotropic displacement  parameters of the non-H atoms (RIGU command in SHELX-2014).  
Relevant crystal data and structure refinement parameters, selected torsion angles, and intra-and 
intermolecular H-bond parameters are listed in Tables S1-S3 for 2a, and in Tables S4-S6 for 3c. 
CCDC 1473792-1473793 contain the supplementary crystallographic data for this paper. These data 
can be obtained from The Cambridge Crystallographic Data Centre via 
www.ccdc.cam.ac.uk/data_request/cif 
 
 
Figure S13. Perspective view of the five independent molecules (A-E) composing the asymmetric 
unit in the X-ray diffraction structure of 3c. In each molecule, the intramolecular H-bond between 
the L-(Me)Val N-H and the maleamide carbonyl oxygen next to the Aib residue is represented by 
a dashed line.  
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Table S1. Crystal data and structure refinement for 2a. 
Identification code  mc262b 
Empirical formula  C32 H55 N7 O9 
Formula weight  681.83 
Temperature  293(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
Unit cell dimensions a = 9.01420(14) Å = 90°. 
 b = 10.94112(14) Å = 90°. 
 c = 38.4416(6) Å  = 90°. 
Volume 3791.32(10) Å3 
Z 4 
Density (calculated) 1.195 Mg/m3 
Absorption coefficient 0.724 mm-1 
F(000) 1472 
Crystal size 0.25  0.20  0.05 mm3 
Theta range for data collection 2.299 to 70.959°. 
Index ranges -11  h  10, -13  k  12, -47  l  41 
Reflections collected 33257 
Independent reflections 7272 [R(int) = 0.0326] 
Completeness to theta = 67.679° 100.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.22453 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7272 / 0 / 433 
Goodness-of-fit on F2 1.031 
Final R indices [I>2sigma(I)] R1 = 0.0406, wR2 = 0.1098 
R indices (all data) R1 = 0.0438, wR2 = 0.1126 
Absolute structure parameter 0.01(6) 
Largest diff. peak and hole 0.269 and -0.225 e.Å-3 
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Table S2.  Selected torsion angles [°] for 2a. 
________________________________________________________________ 
C1F-N6-C6A-C6 -58.4(3) 
N6-C6A-C6B1-C6G1 174.5(2) 
N6-C6A-C6B1-C6G2 -61.3(3) 
CT1-OT-C6-C6A 178.9(2) 
N6-C6A-C6-OT -47.9(3) 
C6A-N6-C1F-C2F -171.0(2) 
N6-C1F-C2F-C3F 159.6(3) 
C1F-C2F-C3F-C4F -174.6(3) 
C2F-C3F-C4F-N1 169.1(3) 
C3F-C4F-N1-C1A -176.2(2) 
C4F-N1-C1A-C1 -54.3(3) 
N1-C1A-C1-N2 -31.4(3) 
C1A-C1-N2-C2A -172.9(2) 
C1-N2-C2A-C2 -48.6(3) 
N2-C2A-C2-N3 -33.5(3) 
C2A-C2-N3-C3A -176.9(2) 
C2-N3-C3A-C3 -51.1(3) 
N3-C3A-C3-N4 -40.4(3) 
C3A-C3-N4-C4A -172.8(2) 
C3-N4-C4A-C4 -66.1(3) 
N4-C4A-C4-N5 -23.3(3) 
C4A-C4-N5-C5A 178.2(2) 
C4-N5-C5A-C5 66.2(4) 
N5-C5A-C5-NT -135.8(3) 
________________________________________________________________ 
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Table S3.  Hydrogen bonds for 2a [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N3-H3...O2F 0.86 2.45 3.292(3) 168 
 N4-H4...O1 0.86 2.15 2.947(3) 155 
 N5-H5...O2 0.86 2.29 3.069(3) 151 
 N6-H6...O6#1 0.86 2.15 2.989(3) 164 
 N1-H1...O3#2 0.86 2.32 3.142(2) 161 
 N2-H2...O5#3 0.86 2.29 2.906(3) 128 
 NT-HT1...O3#4 0.86 2.37 3.197(4) 160 
 NT-HT2...O2#4 0.86 2.50 3.061(4) 124 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+2, y-1/2, -z+1/2;   #2 x, y+1, z;    #3 x+1/2, -y+1/2, -z;  #4 x-1/2, -y-1/2, -z 
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Table S4. Crystal data and structure refinement for 3c. 
 
Identification code  mc265f 
Empirical formula  C19 H32 N2 O6 
Formula weight  384.46 
Temperature  293(2) K 
Wavelength  1.54178 Å 
Crystal system  Orthorhombic 
Space group  P 21 21 21 
Unit cell dimensions a = 12.78876(14) Å = 90°. 
 b = 21.3074(2) Å = 90°. 
 c = 42.2055(6) Å  = 90°. 
Volume 11500.8(2) Å3 
Z 20 
Density (calculated) 1.110 Mg/m3 
Absorption coefficient 0.678 mm-1 
F(000) 4160 
Crystal size 0.40  0.20  0.05 mm3 
Theta range for data collection 2.323 to 51.482°. 
Index ranges -12  h  12, -21  k  21, -42  l  42 
Reflections collected 50259 
Independent reflections 12491 [R(int) = 0.0263] 
Completeness to theta = 51.482° 99.5 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 1.00000 and 0.77746 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 12491 / 975 / 1216 
Goodness-of-fit on F2 1.044 
Final R indices [I>2sigma(I)] R1 = 0.0525, wR2 = 0.1481 
R indices (all data) R1 = 0.0601, wR2 = 0.1558 
Absolute structure parameter 0.04(5) 
Extinction coefficient n/a 
Largest diff. peak and hole 0.683 and -0.276 e.Å-3 
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Table S5.  Selected torsion angles [°] for 3c. 
________________________________________________________________ 
C1M-N1-C1A-C1 -51.7(6) 
N1-C1A-C1B1-C1G1 59.8(6) 
N1-C1A-C1B1-C1G2 -173.3(6) 
N1-C1A-C1-OTA -37.7(6) 
C1A-C1-OTA-CT1A -176.6(7) 
C1-OTA-CT1A-CT4A 180.0(9) 
C1-OTA-CT1A-CT3A 61.5(11) 
C1-OTA-CT1A-CT2A -62.4(11) 
C1A-N1-C1M-C2M -179.1(5) 
O1M-C1M-C2M-C3M 168.4(7) 
N1-C1M-C2M-C3M -12.3(11) 
C1M-C2M-C3M-C4M 1.8(13) 
C2M-C3M-C4M-O2M 15.1(11) 
C2M-C3M-C4M-N2 -166.5(7) 
C3M-C4M-N2-C2A -176.6(6) 
C4M-N2-C2A-C2 -55.0(8) 
N2-C2A-C2-OTB -34.5(9) 
C2A-C2-OTB-CTB 166.0(13) 
C11M-N3-C3A-C3 -46.2(7) 
N3-C3A-C3B1-C3G2 -65.3(7) 
N3-C3A-C3B1-C3G1 168.1(6) 
N3-C3A-C3-OTC -43.8(6) 
C3A-C3-OTC-CT1C 176.3(5) 
C3-OTC-CT1C-CT2C -59.7(11) 
C3-OTC-CT1C-CT3C 67.6(10) 
C3-OTC-CT1C-CT4C -177.4(7) 
C3A-N3-C11M-C12M 171.3(5) 
O11M-C11M-C12M-C13M 165.8(6) 
N3-C11M-C12M-C13M -12.5(10) 
C11M-C12M-C13M-C14M 3.7(12) 
C12M-C13M-C14M-O12M 22.4(11) 
C12M-C13M-C14M-N4 -159.3(7) 
C13M-C14M-N4-C4A -179.8(7) 
C14M-N4-C4A-C4 -46.7(10) 
N4-C4A-C4-OTD -40.4(9) 
C4A-C4-OTD-CTD 177.0(8) 
C21M-N5-C5A-C5 -48.9(6) 
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N5-C5A-C5B1-C5G2 -60.7(7) 
N5-C5A-C5B1-C5G1 172.8(6) 
N5-C5A-C5-OTE -43.3(6) 
C5A-C5-OTE-CT1E 179.6(5) 
C5-OTE-CT1E-CT3E -177.0(6) 
C5-OTE-CT1E-CT2E -58.2(8) 
C5-OTE-CT1E-CT4E 63.0(8) 
C5A-N5-C21M-C22M 179.0(5) 
O21M-C21M-C22M-C23M 166.8(7) 
N5-C21M-C22M-C23M -13.6(11) 
C21M-C22M-C23M-C24M 4.8(12) 
C22M-C23M-C24M-O22M 21.8(11) 
C22M-C23M-C24M-N6 -158.0(7) 
C23M-C24M-N6-C6A -179.6(5) 
C24M-N6-C6A-C6 -44.4(8) 
N6-C6A-C6-OTF -41.8(7) 
C6A-C6-OTF-CTF 173.0(6) 
C31M-N7-C7A-C7 -47.3(7) 
N7-C7A-C7B1-C7G2 -61.8(7) 
N7-C7A-C7B1-C7G1 174.5(6) 
N7-C7A-C7-OTG -47.1(6) 
C7A-C7-OTG-CT1G 176.5(5) 
C7-OTG-CT1G-CT3G -173.1(7) 
C7-OTG-CT1G-CT4G 64.7(9) 
C7-OTG-CT1G-CT2G -57.4(9) 
C7A-N7-C31M-C32M 179.2(5) 
O31M-C31M-C32M-C33M 163.7(6) 
N7-C31M-C32M-C33M -16.5(10) 
C31M-C32M-C33M-C34M 3.3(12) 
C32M-C33M-C34M-O32M 22.5(11) 
C32M-C33M-C34M-N8 -161.7(7) 
C33M-C34M-N8-C8A 179.9(7) 
C34M-N8-C8A-C8 -43.8(11) 
N8-C8A-C8-OTH -44.3(10) 
C8A-C8-OTH-CTH 177.5(8) 
C41M-N9-C9A-C9 -46.3(7) 
N9-C9A-C9B1-C9G1 41.0(9) 
N9-C9A-C9B1-C9G2 167.1(8) 
N9-C9A-C9-OTI -45.0(6) 
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C9A-C9-OTI-CT1I -177.6(5) 
C9-OTI-CT1I-CT4I 63.8(8) 
C9-OTI-CT1I-CT3I -60.4(8) 
C9-OTI-CT1I-CT2I -177.6(6) 
C9A-N9-C41M-C42M 179.9(5) 
O41M-C41M-C42M-C43M 173.9(6) 
N9-C41M-C42M-C43M -5.2(10) 
C41M-C42M-C43M-C44M 5.0(12) 
C42M-C43M-C44M-O42M 12.9(10) 
C42M-C43M-C44M-N10 -168.8(6) 
C43M-C44M-N10-C10A -176.0(5) 
C44M-N10-C10A-C10 -52.9(7) 
N10-C10A-C10-OTL 140.6(5) 
C10A-C10-OTL-CTL -180.0(7) 
________________________________________________________________ 
 
 
Table S6.  Hydrogen bonds for 3c [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N1-H1...O2M 0.86 1.89 2.708(5) 157.5 
 N3-H3...O12M 0.86 1.91 2.715(6) 155.2 
 N5-H5...O22M 0.86 1.93 2.746(6) 157.8 
 N7-H7...O32M 0.86 1.91 2.723(6) 156.0 
 N9-H9...O42M 0.86 1.89 2.706(5) 158.8 
 N2-H2...O31M#1 0.86 2.06 2.911(6) 168.8 
 N4-H4...O21M#2 0.86 2.04 2.875(6) 163.6 
 N6-H6...O11M#1 0.86 2.13 2.970(6) 166.6 
 N8-H8...O1M#2 0.86 2.04 2.883(6) 165.6 
 N10-H10...O41M#3 0.86 2.04 2.877(5) 164.0 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x,y+1/2,-z+1/2    #2 -x+1,y-1/2,-z+1/2    #3 x-1/2,-y+1/2,-z  
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Synthesis and characterization of compounds 
Materials 
N,N-diisopropylethylamine (DIPEA), trifluoroacetic acid (TFA), monoethyl fumarate, LiOH, 
triethylamine (TEA), H-L-Val-OtBu∙HCl, tert-butyl α-bromoisobutyrate, α-bromoisobutyric acid, 
Pd/C catalyst (10% wt. loading), 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC∙HCl) were obtained from Sigma-Aldrich. 1-hydroxy-7-aza-1,2,3-benzotriazole (HOAt) was 
purchased from GL Biochem (Shanghai). 
H-L-(αMe)Val-OH, H-Aib-OMe∙HCl, H-L-Val-OMe and H-D,L-Val-OMe were obtained from 
Bachem.The deuterated solvents DMSO-d6, CDCl3, MeOH-d3 and MeOD-d4 were purchased from 
Euriso-Top (France). 
Methods for the synthesis of H-L-(αMe)Val-OtBu,3 H-Aib4-Gly-NH2,4 N3-Aib4-OMe5 and N3-Aib8-
OMe6 have been reported previously. 
 
 
a) Synthesis of fumaric acid derivative 1 
Synthesis of 14 
 
Monoethyl fumarate (390 mg, 2.7 mmol) and HOAt (365 mg, 2.7 mmol) were dissolved in CH2Cl2. 
The suspension was cooled to 0 °C and EDC∙HCl (500 mg, 2.7 mmol) was added. After complete 
dissolution H-(αMe)Val-OtBu (350 mg, 1.87 mmol) and TEA (400 μL, 2.9 mmol) were added and 
the reaction mixture stirred overnight at r.t. The solvent was removed under reduced pressure and 
the residue dissolved in EtOAc. The organic phase was washed with KHSO4(aq) 5%, NaHCO3(aq) 
5%, brine, dried over MgSO4, filtered and concentrated. The crude was purified via flash 
chromatography (eluant: petroleum ether/EtOAc increasing the solvent mixture polarity from 9:1 to 
8:2). The product was obtained as a colorless oil (500 mg, 85 % yield). 
HRMS (ES+, MeOH) m/z calcd. for C16H27NO5Na ([M+Na]+) 336.1787, found 336.1783. ?????? = -
36.3 (c 1, MeOH). FT-IR ῡmax 3351, 2977, 1727, 1682, 1259, 1368, 1296, 1272, 1150 cm-1. 1H 
NMR (400 MHz, CDCl3) δ 6.91 (d, J = 15.3 Hz, 1H, CH Fum), 6.75 (d, J = 15.3 Hz, 1H, CH Fum), 
6.60 (s, 1H, NH), 4.24 (q, J = 7.1 Hz, 2H, CH2 Et), 2.42 (hept, J = 6.9 Hz, 1H, βCH), 1.63 (s, 3H, 
βCH3), 1.47 (s, 9H, OtBu), 1.31 (t, J = 7.1 Hz, 3H, CH3 Et), 1.01 (d, J = 7.0 Hz, 3H, γCH3), 0.90 (d, 
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J = 6.9 Hz, 3H, γCH3). 13C NMR (101 MHz, CDCl3) δ 172.57, 165.74, 162.55, 137.31, 130.19, 
82.56, 64.33, 61.29, 34.17, 28.08, 19.28, 17.75, 17.67, 14.29. 
 
Synthesis of 1 
 
14 (500 mg, 1.6 mmol) was dissolved in 30 mL of THF and a solution of LiOH (260 mg, 10.8 
mmol) in 10 mL of H2O was added. The solution was stirred at r.t. until TLC indicated complete 
consumption of the starting material. The organic solvent was removed under reduced pressure and 
the aqueous residue was diluted with 10 mL of H2O. The aqueous solution was acidified with HCl 
1M and extracted with EtOAc (3v). The combined organic phases were washed with KHSO4(aq) 5%, 
brine, dried over MgSO4, filtered and concentrated under reduced pressure. The compound was 
recovered as a white solid (400 mg, 88 % yield). 
HRMS (ES+, MeOH) m/z calcd. for C14H23NO5Na ([M+Na]+) 308.1474, found 308.1477. ?????? = -
38.4 (c 1, MeOH). Mp 213-215 °C. FT-IR ῡmax 3297, 2975, 1727, 1640, 1534, 1368, 1276, 1147 
cm-1. 1H NMR (500 MHz, MeOD) δ 8.42 (s, 1H, NH), 7.11 (d, J = 15.5 Hz, 1H, CH Fum), 6.64 (d, 
J = 15.5 Hz, 1H, CH Fum), 2.13-2.03 (m, 1H, βCH), 1.44 (s, 9H, OtBu), 1.42 (s, 3H, βCH3), 1.01 
(d, J = 6.9 Hz, 3H, γCH3), 0.95 (d, J = 6.9 Hz, 3H, γCH3). 13C NMR (101 MHz, MeOD) δ 173.48, 
168.52, 165.68, 137.85, 131.35, 82.35, 64.55, 35.87, 28.20, 17.71, 17.53, 17.50. 
 
 
b) Synthesis of fumaramides 2a-f 
Synthesis of 2a 
 
1 (140 mg, 0.49 mmol) and HOAt (70 mg, 0.51 mmol) were dissolved in CH2Cl2. The suspension 
was cooled to 0 °C and EDC∙HCl (94 mg, 0.49 mmol) was added. After complete dissolution H-
Aib4-Gly-NH2 (150 mg, 0.36 mmol) and DIPEA (100 μL, 0.57 mmol) were added and the reaction 
mixture stirred overnight at r.t. The solvent was removed under reduced pressure and the residue 
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dissolved in EtOAc. The organic phase was washed with KHSO4(aq) 5%, NaHCO3(aq) 5%, brine, 
dried over MgSO4, filtered and concentrated. The crude was purified via flash chromatography 
(eluant: CH2Cl2/MeOH 92:8). The product was obtained as a white solid (190 mg, 77% yield). 
HRMS (ES+, MeOH) m/z calcd. for C32H55N7O9Na ([M+Na]+) 704.3959, found 704.3976. ?????? = -
8.5 (c 1, MeOH). Mp 263-265 °C. FT-IR ῡmax 3293, 2930, 1654, 1537, 1468, 1383, 1364 cm-1. 1H 
NMR (500 MHz, CD3CN) δ 7.80 (s, 1H, NH Aib3), 7.79 (t, J = 6.5 Hz, 1H, NH Gly), 7.64 (s, 1H, 
NH Aib4), 7.43 (s, 1H, NH Aib1), 7.14 (s, 1H, NH Aib2), 7.11 (s br, 1H, NHa GlyNH2), 6.95 (d, J = 
15.0 Hz, 1H, CH Fum), 6.90 (s, 1H, NH αMeVal), 6.85 (d, J = 15.0 Hz, 1H, CH Fum), 5.65 (s, 1H, 
NHb GlyNH2), 3.67 (d, J = 6.4 Hz, 2H, CH2 Gly), 2.10-2.06 (m, 1H, βCH αMeVal), 1.45 (s, 6H, 2x 
βCH3 Aib), 1.44 (s, 6H, 2x βCH3 Aib), 1.43 (s, 6H, 2x βCH3 Aib), 1.41 (s, 9H, OtBu), 1.40 (s, 3H, 
βCH3 αMeVal), 1.35 (s, 5H, 2x βCH3 Aib), 0.99 (d, J = 6.9 Hz, 3H, γCH3 αMeVal), 0.92 (d, J = 6.9 
Hz, 3H, γCH3 αMeVal). 13C NMR (101 MHz, CD3CN) δ 177.07 (CO Aib3), 176.60 (CO Aib2), 
176.27 (CO Aib4), 175.30 (CO Aib1), 173.24 (CO Gly), 172.59 (CO αMeVal), 165.62 (CbO Fum), 
164.18 (CaO Fum), 134.74 (Ca Fum), 132.98 (Cb Fum), 81.41 (C OtBu), 64.04 (αC αMeVal), 57.72 
(αC Aib), 57.54 (αC Aib), 57.51 (αC Aib), 57.48 (αC Aib), 43.60 (αC Gly), 35.49 (βCH αMeVal), 
28.07 (CH3 OtBu), 25.54 (βC Aib4), 25.21 (βC Aib3), 25.10 (βC Aib2), 24.91 (βC Aib1), 17.67 
(βCH3 αMeVal), 17.55 (C αMeVal), 17.44 (C αMeVal). 
 
Synthesis of 2b 
 
 
OtBu-(αMe)Val-Mal-Aib4-OH (100 mg, 0.16 mmol) was dissolved in 4 mL of dry CH2Cl2 and 
EDC∙HCl (38 mg, 0.2 mmol) was added. The solution was stirred at r.t. for 1 h. The solvent was 
removed under reduced pressure and the residue dissolved in EtOAc. The organic solution was 
washed with KHSO4, brine, dried over MgSO4, filtered and concentrated under reduced pressure 
The crude oxazolone was then placed under high vacuum before being dissolved in CH3CN. Then 
H-Aib4-Gly-NH2 (100 mg, 0.24 mmol) was added. The reaction was stirred under reflux for 5 d. 
The solution was diluted with CH2Cl2 and the precipitate was recovered by filtration. After 
purification by flash chromatography (eluant: CH2Cl2/MeOH 95:5), the pure product was recovered 
as a white solid (55 mg, 33 % yield). 
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HRMS (ES+ MeOH) m/z calcd. for C48H83N11O13Na ([M+Na]+) 1044.6064, found 1044.6060. ?????? 
= -5.3 (c 1, MeOH). Mp decompose >270 °C. FT-IR ῡmax 3289, 2981, 1657, 1539, 1384, 1363, 
1228 cm-1. 1H NMR (500 MHz, CD3CN) δ 7.84 (m, 2H, 2x NH), 7.81 (s, 1H, NH), 7.79 (m, 3H, 
NH), 7.66 (s, 1H, NH), 7.51 (s, 1H, NH), 7.20 (s, 1H, NH), 7.12 (s, 1H, NH), 6.96 (d, J = 15.0 Hz, 
1H, CH Fum), 6.91 (s, 1H, NH), 6.87 (d, J = 15.0 Hz, 1H, CH Fum), 5.65 (s, 1H, NH), 3.67 (d, J = 
5.7 Hz, 2H, CH2 Gly), 2.08 (m, 1H, βCH αMeVal), 1.48 (s, 6H, 2x βCH3 Aib), 1.45 (s, 6H, 2x 
βCH3 Aib), 1.44 (s, 18H, 6x βCH3 Aib), 1.43 (s, 6H, 2x βCH3 Aib), 1.42 (s, 6H, 2x βCH3 Aib), 1.41 
(s, 9H, OtBu), 1.40 (s, 3H, βCH3 αMeVal), 1.36 (s, 6H, 2x βCH3 Aib), 0.99 (d, J = 6.9 Hz, 3H, 
γCH3 αMeVal), 0.92 (d, J = 6.9 Hz, 3H, γCH3 αMeVal). 13C NMR (101 MHz, CD3CN) δ 177.32, 
177.09, 176.98, 176.95, 176.94, 176.30, 175.39, 173.22, 172.56, 165.66, 164.18, 134.75, 132.99, 
81.44, 64.07, 57.72, 57.57, 57.48, 57.43, 57.33, 57.30, 57.27, 43.61, 35.47, 28.06, 25.19, 17.76, 
17.53, 17.42. 
 
Synthesis of 2c 
1 (35 mg, 0.12 mmol) and HOAt (17 mg, 0.12 mmol) were dissolved in dry CH2Cl2. The 
suspension was cooled to 0 °C and EDC∙HCl (23 mg, 0.12 mmol) was added. After complete 
dissolution H-Aib-OMe∙HCl (37 mg, 0.24 mmol) and DIPEA (65 μL, 0.37 mmol) were added and 
the reaction mixture stirred overnight at r.t. The solvent was removed under reduced pressure and 
the residue dissolved in EtOAc. The organic phase was washed with KHSO4(aq) 5%, NaHCO3(aq) 
5%, brine, dried over MgSO4, filtered and concentrated. The product was obtained as a white solid 
after precipitation from EtOAc/petroleum ether (40 mg, 85% yield). 
HRMS (ES+ MeOH) m/z calcd. for C19H33N2O6 ([M+H]+) 385.2333, found 385.2403. Mp 149-152 
°C. FT-IR ῡmax 3351, 2978, 1730, 1649, 1533, 1367, 1335, 1283, 1152 cm-1. 
1H NMR (500 MHz, CD3CN) δ 7.09 (s, 1H, NH Aib), 6.87 (d, J = 15.1 Hz, 1H, CH Fum), 6.80 (s, 
1H, NH αMeVal), 6.75 (d, J = 15.1 Hz, 1H, CH Fum), 3.62 (s, 3H, OMe), 2.05 (dt, J = 13.8, 6.9 
Hz, 1H, βCH αMeVal), 1.44 (s, 6H, 2x βCH3 Aib), 1.40 (s, 9H, OtBu), 1.38 (s, 3H, βCH3 αMeVal), 
0.97 (d, J = 6.9 Hz, 3H, γCH3 αMeVal), 0.90 (d, J = 6.9 Hz, 3H, γCH3 αMeVal). 13C NMR (101 
MHz, CD3CN) δ 175.24, 172.67, 164.38, 134.40, 132.99, 81.43, 64.06, 56.93, 52.78, 35.51, 28.15, 
25.21, 17.87, 17.60, 17.47. 
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Synthesis of 2d 
1 (35 mg, 0.12 mmol) and HOAt (17 mg, 0.12 mmol) were dissolved in dry CH2Cl2. The 
suspension was cooled to 0 °C and EDC∙HCl (23 mg, 0.12 mmol) was added. After complete 
dissolution H-Aib2-OMe (48 mg, 0.24 mmol) and DIPEA (22 μL, 0.12 mmol) were added and the 
reaction mixture stirred overnight at r.t. The solvent was removed under reduced pressure and the 
residue dissolved in EtOAc. The organic phase was washed with KHSO4(aq) 5%, NaHCO3(aq) 5%, 
brine, dried over MgSO4, filtered and concentrated. The product was obtained as a white solid after 
precipitation from EtOAc/petroleum ether (45 mg, 80% yield). 
HRMS (ES+ MeOH) m/z calcd. for C23H40N3O7 ([M+H]+) 470.2871, found 470.2853. Mp 89-90 °C. 
FT-IR ῡmax 3356, 2980, 1733, 1652, 1532, 1367, 1277, 1151 cm-1. 1H NMR (500 MHz, CD3CN) δ 
7.02 (s, 1H, NH Aib1), 6.96 (s, 1H, NH Aib2), 6.88 (d, J = 15.0 Hz, 1H, CH Fum), 6.81 (d, J = 15.1 
Hz, 2H, CH Fum and NH αMeVal), 3.60 (s, 3H, OMe), 2.05 (dt, J = 13.7, 6.8 Hz, 1H, βCH 
αMeVal), 1.42 (s, 6H, 2x βCH3 Aib), 1.40 (s, 9H, OtBu), 1.39 (s, 3H, βCH3 αMeVal), 1.37 (s, 6H, 
2x βCH3 Aib), 0.97 (d, J = 6.9 Hz, 3H, γCH3 αMeVal), 0.91 (d, J = 6.8 Hz, 3H, γCH3 αMeVal). 13C 
NMR (101 MHz, CD3CN) δ 175.78, 174.25, 172.67, 164.49, 164.46, 133.95, 133.89, 81.45, 64.07, 
57.88, 56.77, 52.59, 35.54, 28.16, 25.23, 25.21, 17.88, 17.60, 17.47. 
 
Synthesis of 2e 
 
1 (230 mg, 0.81 mmol) and HOAt (110 mg, 0.81 mmol) were dissolved in dry CH2Cl2. The 
suspension was cooled to 0 °C and EDC∙HCl (155 mg, 0.81 mmol) was added. After complete 
dissolution H-Aib4-OMe (200 mg, 0.54 mmol, prepared by the quantitative hydrogenolysis of 
N3Aib4-OMe) and DIPEA (140 μL, 0.81 mmol) were added and the reaction mixture stirred 
overnight at r. t. The solvent was removed under reduced pressure and the residue dissolved in 
EtOAc. The organic phase was washed with KHSO4(aq) 5%, NaHCO3(aq) 5%, brine, dried over 
MgSO4, filtered and concentrated. The crude was purified via flash chromatography using as eluent 
94:6 CH2Cl2/MeOH. The product was obtained as a white solid (280 mg, 81% yield). 
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HRMS (ES+, MeOH) m/z calcd. for C31H54N5O9 ([M+H]+) 640.3916, found 640.3922. ?????? = -8.1 
(c 1, MeOH). Mp 136-137 °C. FT-IR ῡmax 3309, 2983, 1728, 1645, 1530, 1457, 1385, 1365, 1273, 
1222, 1151, 732 cm-1. 
1H NMR (500 MHz, CD3CN) δ 7.42 (s, 1H, NH Aib4), 7.37 (s, 1H, NH Aib1), 7.34 (s, 1H, NH 
Aib3), 7.01 (s, 1H, NH Aib2), 6.93 (d, J = 15.0 Hz, 1H, CH Fum), 6.89 (s, 1H, NH αMeVal), 6.84 
(d, J = 15.0 Hz, 1H, CH Fum), 3.58 (s, 3H, OMe), 2.06 (dq, J = 13.7, 6.9 Hz, 1H, βCH αMeVal), 
1.42 (s, 6H, 2x βCH3 Aib3), 1.42 (s, 6H, 2x βCH3 Aib1), 1.40 (s, 9H, OtBu), 1.39 (s, 9H, 2x βCH3 
Aib4 and βCH3 αMeVal), 1.31 (s, 6H, 2x βCH3 Aib2), 0.98 (d, J = 6.9 Hz, 3H, γCH3 αMeVal), 0.92 
(d, J = 6.9 Hz, 3H, γCH3 αMeVal). 13C NMR (101 MHz, CDCl3) δ 175.85, 174.80, 173.66, 173.02, 
172.43, 164.97, 163.10, 135.26, 131.82, 82.14, 64.12, 57.48, 57.03, 56.92, 55.98, 52.32, 34.37, 
29.85, 28.12, 25.65, 25.39, 25.05, 24.98, 18.65, 17.70, 17.67. 
 
Synthesis of 2f 
 
1 (100 mg, 0.35 mmol) and HOAt (50 mg, 0.37 mmol) were dissolved in dry CH2Cl2. The 
suspension was cooled to 0 °C and EDC∙HCl (70 mg, 0.36 mmol) was added. After complete 
dissolution, H-Aib8-OMe (140 mg, 0.2 mmol, prepared by the quantitative hydrogenolysis of 
N3Aib8-OMe) and DIPEA (60 μL, 0.36 mmol) were added and the reaction mixture stirred 
overnight at r.t. The solvent was removed under reduced pressure and the residue dissolved in 
EtOAc. The organic phase was washed with KHSO4(aq) 5%, NaHCO3(aq) 5%, brine, dried over 
MgSO4, filtered and concentrated. The product was obtained as a white solid after precipitation 
from EtOAc/petroleum ether (150 mg, 77% yield). 
HRMS (ES+ MeOH) m/z calcd. for C47H82N9O13 ([M+H]+) 980.6027, found 980.6179. Mp 172-175 
°C. FT-IR ῡmax 3310, 2986, 2942, 1733, 1659, 1535, 1467, 1458, 1385, 1364, 1229, 1152 cm-1. 1H 
NMR (400 MHz, CDCl3) δ 7.92 (s, 1H, NH), 7.85 (s, 1H, NH), 7.80 (s, 1H, NH), 7.75 (s, 2H, 2x 
NH), 7.72 (s, 1H, NH), 7.49 (s, 1H, NH), 7.27 (s, 1H, NH), 7.08 (s, 1H, NH), 6.95-6.73 (m, 2H, AB 
system CH2 Fum), 3.69 (s, 3H, OMe), 2.34 (dt, J = 14.1, 6.9 Hz, 1H, βCH αMeVal), 1.78 (s, 12H, 
4x βCH3 Aib), 1.57 (s, 3H, βCH3 αMeVal), 1.52 (s, 12H, 4x βCH3 Aib), 1.49 (s, 12H, 4x βCH3 
Aib), 1.47 (s, 15H, OtBu and 2x βCH3 Aib), 1.41 (s, 6H, 2x βCH3 Aib), 1.02 (d, J = 6.8 Hz, 3H, 
γCH3 αMeVal), 0.93 (d, J = 6.8 Hz, 3H, γCH3 αMeVal). 13C NMR (101 MHz, CDCl3) δ 176.49, 
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176.18, 176.09, 175.72, 175.22, 175.19, 174.69, 172.47, 165.44, 81.97, 64.11, 57.41, 56.99, 56.87, 
56.73, 56.70, 56.26, 52.42, 34.47, 28.16, 25.12, 24.93, 18.83, 17.76. 
 
c) Synthesis of 3a 
 
A solution of 6a (30 mg, 0.044 mmol) in 3 mL of MeOH was irradiated in a quartz cuvette at 254 
nm for 2 h. The solvent was removed under reduced pressure obtaining the crude product. Pure 
compound 7a was obtained by semipreparative HPLC, after freeze-drying as a white solid. 
FT-IR ῡmax 3289, 2922, 1650, 1539, 1468, 1383, 1364 cm-1. 1H NMR (500 MHz, CD3CN) δ 8.61 (s, 
1H, NH Aib2), 7.84 (s, 1H, NH Aib3), 7.82 (t, J = 6.2 Hz, 1H, NH Gly), 7.70 (s, 1H, NH Aib4), 7.46 
(s, 1H, NH Aib1), 7.10 (s br, 1H, GlyNH2), 7.05 (s, 1H, NH αMeVal), 6.29 (d, J = 12.0 Hz, 1H, CH 
Mal), 6.20 (d, J = 12.0 Hz, 1H, CH Mal), 5.64 (s, 1H, GlyNH2), 2.11-2.06 (m, 1H, βCH αMeVal), 
1.44 (s, 12H, OtBu and βCH3 Aib), 1.43 (s, 3H, βCH3 Aib), 1.42 (s, 3H, βCH3 Aib), 1.41 (s, 6H, 2x 
βCH3 Aib), 1.38 (s, 3H, βCH3 αMeVal), 1.36 (s, 6H, 2x βCH3 Aib), 1.35 (s, 3H, βCH3 Aib), 0.99 
(d, J = 6.9 Hz, 3H, γCH3 αMeVal), 0.92 (d, J = 6.9 Hz, 3H, γCH3 αMeVal). 13C NMR (101 MHz, 
CD3CN) δ 177.35 (CO Aib2), 176.93 (CO Aib3), 176.30 (CO Aib4), 175.88 (CO Aib1), 173.26 (CO 
Gly), 172.31 (CO αMeVal), 168.69 (CbO Mal), 164.53 (CaO Mal), 136.05 (Cb Mal), 126.97 (Ca 
Mal), 81.63 (C OtBu), 64.05 (αC αMeVal), 57.71 (αC Aib), 57.57 (αC Aib x2), 57.33 (αC Aib), 
43.60 (αC Gly), 35.46 (βC αMeVal), 28.19 (CH3 OtBu), 26.43 (βC Aib4), 26.23 (βC Aib2), 26.17 
(βC Aib3), 26.06 (βC Aib1), 24.66 (βC Aib4), 24.46 (βC Aib1), 24.33 (βC Aib2), 24.26 (βC Aib3), 
17.52 (βCH3 αMeVal), 17.40 (C αMeVal), 17.37 (C αMeVal). 
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d) Synthesis of 3c 
Synthesis of 15 
 
H-(αMe)Val-OtBu (150 mg, 0.8 mmol) was dissolved in 2 mL of dry CH3CN and TEA (100 μL, 
0.71 mmol) were added. Maleic anhydride (70 mg, 0.71 mmol) was dissolved in 1 mL of dry 
CH3CN and added to the solution of the amino acid. The reaction mixture stirred overnight at r.t. 
The solvent was removed under reduced pressure and the residue dissolved in EtOAc. The organic 
phase was washed with KHSO4(aq) 5% and brine, dried over Na2SO4, filtered and concentrated. The 
product was obtained as a white solid (170 mg, 74% yield). 
HRMS (ES+, MeOH) m/z calcd. for C14H24NO5 ([M+H]+) 286.1649, found 286.1703. Mp 156-159 
°C. FT-IR ῡmax 3306, 3002, 2980, 1727, 1712, 1632, 1593, 1558, 1490, 1368, 1147, 858 cm-1. 1H 
NMR (500 MHz, CDCl3) δ 7.28 (s, 1H, NH), 6.36 (d, J = 12.8 Hz, 1H, CH Mal), 6.29 (d, J = 12.9 
Hz, 1H, CH Mal), 2.50-2.37 (m, 1H, βCH), 1.65 (s, 3H, βCH3), 1.49 (s, 9H, OtBu), 1.04 (d, J = 7.0 
Hz, 3H, γCH3), 0.92 (d, J = 6.9 Hz, 3H, γCH3). 13C NMR (101 MHz, CDCl3) δ 171.71, 165.22, 
164.68, 136.95, 131.52, 83.40, 65.32, 33.84, 27.88, 18.82, 17.53. 
 
Synthesis of 3c 
 
15 (50 mg, 0.17 mmol) and HOAt (23 mg, 0.17 mmol) were dissolved in dry CH2Cl2. The 
suspension was cooled to 0 °C and EDC∙HCl (33 mg, 0.17 mmol) was added. After complete 
dissolution H-Aib-OMe∙HCl (54 mg, 0.35 mmol) and DIPEA (90 μL, 0.52 mmol) were added and 
the reaction mixture stirred overnight at r.t. The solvent was removed under reduced pressure and 
the residue dissolved in EtOAc. The organic phase was washed with KHSO4(aq) 5%, NaHCO3(aq) 
5%, brine, dried over MgSO4, filtered and concentrated. The product was obtained as an oil (50 mg, 
75% yield). 
HRMS (ES+, MeOH) m/z calcd. for C19H33N2O6 ([M+H]+) 385.2333, found 385.2435. FT-IR ῡmax 
3280, 2978, 1748, 1729, 1671, 1620, 1578, 1548, 1368, 1286, 1263, 1149, 854 cm-1. 
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1H NMR (500 MHz, CD3CN) δ 8.94 (s, 1H, NH Aib), 8.70 (s, 1H, NH αMeVal), 6.12 (d, J = 13.4 
Hz, 1H, CH Mal), 6.06 (d, J = 13.4 Hz, 1H, CH Mal), 3.62 (s, 3H, OMe), 2.02 (dt, J = 13.7, 6.9 Hz, 
1H, βCH αMeVal), 1.44 (s, 3H, βCH3 Aib), 1.43 (s, 3H, βCH3 Aib), 1.40 (s, 9H, OtBu), 1.36 (s, 
3H, βCH3 αMeVal), 0.98 (d, J = 6.9 Hz, 3H, γCH3 αMeVal), 0.91 (d, J = 6.9 Hz, 3H, γCH3 
αMeVal). 13C NMR (101 MHz, CD3CN) δ 175.15, 165.20, 134.14, 132.84, 81.36, 64.09, 56.86, 
52.76, 35.73, 28.15, 25.16, 25.08, 17.67, 17.61, 17.43. 
 
 
e) Synthesis of carboxylic acids 4a-b 
Synthesis of 4a 
2e (320 mg, 0.54 mmol) was dissolved in 15 mL of THF and a solution of LiOH (85 mg, 3.5 mmol) 
in 5 mL of water was added. The solution was stirred at 40°C for 24 h. The organic solvent was 
removed under reduced pressure and the aqueous phase was acidified with HCl 1M. The compound 
was extracted using EtOAc (3v). The organic phase was washed with KHSO4(aq) 5% and brine, 
dried over MgSO4, filtered and concentrated under reduced pressure. The product was obtained as a 
white solid (230 mg, 73% yield). 
HRMS (ES+, MeOH) m/z calcd. for C30H51N5O9Na ([M+Na]+) 648.3579, found 648.3584. ?????? = -
8 (c 1, MeOH). Mp 152-154 °C. FT-IR ῡmax 3305, 2982, 1728, 1650, 1534, 1458, 1385, 1260, 1225, 
1151 cm-1. 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H, NH), 7.89 (s, 1H, NH), 7.87 (s, 1H, NH), 
7.23 (s, 1H, NH), 6.97 (s, 1H, NH), 6.87 (m, 2H, AB system CH2 Fum), 2.40 (m, 1H, βCH 
αMeVal), 1.59 (s, 3H, βCH3 αMeVal), 1.56 (s, 6H, 2x βCH3 Aib), 1.52 (s, 6H, 2x βCH3 Aib), 1.50 
(s, 6H, 2x βCH3 Aib), 1.47 (s, 9H, OtBu), 1.43 (s, 6H, 2x βCH3 Aib), 1.01 (d, J = 6.7 Hz, 3H, γCH3 
αMeVal), 0.91 (d, J = 6.7 Hz, 3H, γCH3 αMeVal). 13C NMR (101 MHz, CDCl3) δ 176.78, 175.75, 
175.56, 174.53, 172.66, 165.39, 163.86, 133.74, 133.07, 82.43, 64.30, 57.33, 56.97, 56.91, 34.21, 
29.85, 28.11, 25.19, 24.85, 18.98, 17.78, 17.73. 
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Synthesis of 4b 
 
2f (120 mg, 0.12 mmol) was dissolved in 10 mL of THF and a solution of LiOH (20 mg, 0.86 
mmol) in 5 mL of water was added. The solution was stirred at 60 °C for 48 h, The solution was 
diluted with CH2Cl2 and the aqueous phase was acidified with HCl 1M. The compound was 
extracted using CH2Cl2 (3v). The organic phase was washed with KHSO4(aq) 5% and brine, dried 
over MgSO4, filtered and concentrated under reduced pressure. The crude was purified via flash 
chromatography (eluant: CH2Cl2/MeOH, 93:7→8:2). The product was obtained as a white solid (80 
mg, 68% yield). 
HRMS (ES+ MeOH) m/z calcd. for C46H80N9O13 ([M+H]+) 966.5870, found 966.6056. Mp 190-193 
°C. FT-IR ῡmax 3309, 2985, 2939, 1728, 1659, 1535, 1385, 1365, 1228 cm-1. 
1H NMR (400 MHz, MeOD) δ 7.10 (d, J = 15.1 Hz, 1H, CH Fum), 6.92 (d, J = 15.1 Hz, 1H, CH 
Fum), 2.09 (dt, J = 13.6, 6.7 Hz, 1H, βCH αMeVal), 1.52 (s, 6H, 2x βCH3 Aib), 1.51 (s, 6H, 2x 
βCH3 Aib), 1.49 (s, 6H, 2x βCH3 Aib), 1.48 (s br, 24H, 4x βCH3 Aib), 1.44 (s, 9H, OtBu), 1.42 (s, 
3H, βCH3 αMeVal), 1.40 (s, 6H, 2x βCH3 Aib), 1.01 (d, J = 6.7 Hz, 3H, γCH3 αMeVal), 0.96 (d, J 
= 6.7 Hz, 3H, γCH3 αMeVal). 13C NMR (101 MHz, MeOD) δ 177.63, 177.48, 177.42, 177.15, 
177.01, 176.74, 176.21, 173.54, 166.31, 166.02, 134.67, 133.75, 82.33, 64.57, 57.95, 57.89, 57.83, 
57.79, 57.73, 35.86, 28.24, 25.49, 25.14, 17.72, 17.69, 17.56.  
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f) Synthesis of 12 
Synthesis of 16 
 
Monoethyl fumarate (90 mg, 0.62 mmol) and HOAt (85 mg, 0.62 mmol) were dissolved in dry 
CH2Cl2. The suspension was cooled to 0 °C and EDC∙HCl (120 mg, 0.62 mmol) was added. After 
complete dissolution, H-Aib4-Gly-NH2 (130 mg, 0.31 mmol) and TEA (90 μL, 0.65 mmol) were 
added and the reaction mixture stirred for 48 h at r.t. The precipitate collected and washed with 
CH2Cl2. The product was recovered after precipitation from MeOH/Et2O obtaining a white solid 
(100 mg, 60% yield). 
HRMS (ES+, MeOH) m/z calcd. for C24H40N6O8Na ([M+Na]+) 563.2805, found 563.2794. Mp 274-
275 °C. FT-IR ῡmax 3264, 2985, 1720, 1652, 1533, 1455, 1386, 1363, 1281, 1223, 1172 cm-1. 
1H NMR (400 MHz, MeOD) δ 7.10 (d, J = 15.4 Hz, 1H, CH Fum), 6.74 (d, J = 15.5 Hz, 1H, CH 
Fum), 4.26 (q, J = 7.1 Hz, 2H, CH2 Et), 3.83 (s, 2H, CH2 Gly), 1.50 (s, 6H, 2x βCH3 Aib), 1.49 (s, 
6H, 2x βCH3 Aib), 1.47 (s, 6H, 2x βCH3 Aib), 1.39 (s, 6H, 2x βCH3 Aib), 1.31 (t, J = 7.1 Hz, 3H, 
CH3 Et). 13C NMR (101 MHz, MeOD) δ 178.09, 178.05, 177.81, 176.09, 175.40, 166.79, 165.65, 
137.58, 131.26, 62.32, 58.14, 58.03, 57.88, 57.79, 43.68, 25.58, 25.27, 14.45. 
 
Synthesis of 10 
 
16 (70 mg, 0.13 mmol) was dissolved in 6 mL of THF and a solution of LiOH (22 mg, 0.92 mmol) 
in 4 mL of water was added. The solution was stirred at r.t. for 1 h. The organic solvent was 
removed under reduced pressure and the aqueous phase was acidified with HCl 1M. After 24 h, the 
compound precipitated from the solution was recovered by filtration. The product was obtained as a 
white solid (50 mg, 73% yield). 
HRMS (ES+, MeOH) m/z calcd. for C22H36N6O8Na ([M+Na]+) 535.2492, found 535.2493. Mp 274-
275 °C. FT-IR ῡmax 3300, 2986, 1659, 1537, 1386, 1224 cm-1. 
1H NMR (400 MHz, MeOD) δ 7.07 (d, J = 15.4 Hz, 1H, CH Fum), 6.71 (d, J = 15.4 Hz, 1H, CH 
Fum), 3.83 (s, 2H, CH2 Gly), 1.50 (s, 6H, 2x βCH3 Aib), 1.49 (s, 6H, 2x βCH3 Aib), 1.47 (s, 6H, 2x 
βCH3 Aib), 1.39 (s, 6H, 2x βCH3 Aib). 13C NMR (101 MHz, MeOD) δ 178.17, 178.12, 178.11, 
S32 
178.09, 177.92, 176.14, 175.41, 168.38, 165.86, 137.55, 131.85, 58.23, 58.14, 57.85, 57.81, 43.68, 
25.58, 25.30, 25.08. 
 
Synthesis of N3-Aib4-Ala-OtBu (17) 
 
N3-Aib4-OH (230 mg, 0.6 mmol) and HOAt (106 mg, 0.77 mmol) were dissolved in dry CH2Cl2. 
After cooling to 0 °C EDC∙HCl (120 mg, 0.6 mmol) was added. Then H-Ala-OtBu∙HCl (217 mg, 
1.2 mmol) and TEA (250 μL, 1.8 mmol) were added and the reaction mixture stirred for 48 h at r.t. 
The reaction mixture was diluted with CH2Cl2 and washed with KHSO4(aq) 5%, NaHCO3(aq) 5%, 
brine. The organic phase was dried over MgSO4, filtered and concentrated. The crude was purified 
via flash chromatography (eluant: CH2Cl2/MeOH 93:7), yielding the product as a white solid (260 
mg, 85 % yield). 
HRMS (ES+, MeOH) m/z calcd. for C23H41N7O6Na ([M+Na]+) 534.3016, found 534.3008. ?????? = -
53.1 (c 1, MeOH). Mp 164-166 °C. FT-IR ῡmax 3325, 2982, 2112, 1732, 1655, 1519, 1457, 1382, 
1365, 1223, 1152 cm-1. 
1H NMR (400 MHz, MeOD) δ 4.19 (q, J = 7.3 Hz, 1H, αCH Ala), 1.53 (s, 3H; βCH3 Aib), 1.52 (s, 
6H, 2x βCH3 Aib), 1.49 (s, 3H, βCH3 Aib), 1.44 (s, 6H, 2x βCH3 Aib), 1.44 (s, 9H, OtBu), 1.42 (d, 
J = 7.4 Hz, 3H, βCH3 Ala), 1.39 (s, 3H, βCH3 Aib), 1.35 (s, 3H, βCH3 Aib). 13C NMR (101 MHz, 
MeOD) δ 177.21, 176.35, 176.25, 174.61, 173.64, 82.13, 64.75, 57.97, 57.94, 57.80, 50.77, 28.22, 
27.41, 26.74, 25.52, 24.53, 24.46, 24.17, 24.12, 23.91, 17.10. 
 
Synthesis of H-Aib4-Ala-OtBu (11) 
 
N3-Aib4-Ala-OtBu (210 mg, 0.41 mmol) was dissolved in 8 mL of EtOH under a nitrogen 
atmosphere. Pd/C catalyst (30 mg) was carefully added and the reaction mixture stirred under H2 
atmosphere for 24 h. The catalyst was removed by filtration through a pad of Celite and the filtrate 
concentrated under reduced pressure to yield the product as a white solid (170 mg, 85% yield). 
HRMS (ES+, MeOH) m/z calcd. for C23H43N5O6Na ([M+Na]+) 508.3111, found 508.3114. ?????? = -
52.3 (c 1, MeOH). Mp 179-181 °C. FT-IR ῡmax 3308, 2981, 1730, 1653, 1525, 1456, 1382, 1363, 
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1226, 1165 cm-1. 1H NMR (400 MHz, MeOD) δ 4.20 (q, J = 7.3 Hz, 1H, αCH Ala), 1.52 (s, 3H, 
βCH3 Aib), 1.50 (s, 3H, βCH3 Aib), 1.44 (s, 15H, OtBu and 2x βCH3 Aib), 1.42 (d, J = 7.4 Hz, 3H, 
βCH3 Ala), 1.40 (s, 3H, βCH3 Aib), 1.36 (s, 3H, βCH3 Aib), 1.33 (s, 3H, βCH3 Aib), 1.32 (s, 3H, 
βCH3 Aib). 13C NMR (101 MHz, MeOD) δ 179.61, 177.26, 176.62, 176.49, 173.66, 82.13, 57.96, 
57.74, 57.40, 55.67, 50.75, 28.54, 28.23, 28.08, 27.43, 26.83, 25.70, 24.20, 24.17, 24.00, 17.12. 
 
Synthesis of OtBu-Ala-Aib4-Fum-Aib4-Gly-NH2 (12) 
 
10 (33 mg, 0.062 mmol) and HOAt (10 mg, 0.073 mmol) were dissolved in dry CH2Cl2. After 
cooling to 0 °C EDC∙HCl (12 mg, 0.062 mmol) was added. Then 11 (35 mg, 0.072 mmol) and 
DIPEA (20 μL, 0.11 mmol) were added and the reaction mixture stirred for 48 h at r.t. The solid 
was recovered and washed with CH2Cl2. The crude product was purified via flash chromatography 
(eluant: CH2Cl2/MeOH 90:15). The product was recovered as a white solid (20 mg, 33 % yield). 
HRMS (ES+, MeOH) m/z calcd. for C45H78N11O13 ([M+H]+) 980.5781, found 980.5770. ?????? = 
+11 (c 0.1, MeOH). Mp >267 °C decompose. FT-IR ῡmax 3295, 2985, 1656, 1537, 1384, 1364, 1226 
cm-1.1H NMR (500 MHz, MeOD) δ 7.08 (s, 2H, CH2 Fum), 4.22 (q, J = 7.3 Hz, 1H, αCH Ala), 3.83 
(s, 2H, CH2 Gly), 1.53 (s, 3H, βCH3 Aib), 1.52 (s, 3H, βCH3 Aib), 1.51 (s, 12H, 4x βCH3 Aib), 1.50 
(s, 3H, βCH3 Aib), 1.47 (s, 3H, βCH3 Aib), 1.47 (s, 6H, 2x βCH3 Aib), 1.46 (s, 6H, 2x βCH3 Aib), 
1.45 (s, 9H, OtBu), 1.44 (s, 3H, βCH3 Aib), 1.43 (d, J = 7.4 Hz, 3H, βCH3 Ala), 1.38 (s, 3H, βCH3 
Aib), 1.37 (s, 3H, βCH3 Aib), 1.34 (s, 3H, βCH3 Aib). 
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Figure S14. 1H NMR (400 MHz) spectra of 14 in CDCl3. 
 
Figure S15. 13C NMR (101 MHz) spectra of 14 in CDCl3.  
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Figure S16. 1H NMR (500 MHz) spectra of 1 in MeOD. 
 
Figure S17. 13C NMR (101 MHz) spectra of 1 in MeOD.  
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Figure S18. 1H NMR (500 MHz) spectra of 2a in CD3CN. 
 
Figure S19. 13C NMR (101 MHz) spectra of 2a in CD3CN.  
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Figure S20. 1H NMR (500 MHz) spectra of 2b in CD3CN. 
 
Figure S21. 13C NMR (101 MHz) spectra of 2b in CD3CN.  
S38 
 
Figure S22. 1H NMR (500 MHz) spectra of 2c in CD3CN. 
 
Figure S23. 13C NMR (101 MHz) spectra of 2c in CD3CN.  
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Figure S24. 1H NMR (500 MHz) spectra of 2d in CD3CN. 
 
Figure S25. 13C NMR (101 MHz) spectra of 2d in CD3CN.  
S40 
 
Figure S26. 1H NMR (500 MHz) spectra of 2e in CD3CN. 
 
Figure S27. 13C NMR (101 MHz) spectra of 2e in CDCl3.  
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Figure S28. 1H NMR (400 MHz) spectra of 2f in CDCl3. 
 
Figure S29. 13C NMR (101 MHz) spectra of 2f in CDCl3.  
S42 
 
Figure S30. 1H NMR (500 MHz) spectra of 3a in CD3CN. 
 
Figure S31. 13C NMR (101 MHz) spectra of 3a in CD3CN.  
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Figure S32. 1H NMR (500 MHz) spectra of 15 in CDCl3. 
 
Figure S33. 13C NMR (101 MHz) spectra of 15 in CDCl3.  
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Figure S34. 1H NMR (500 MHz) spectra of 3c in CD3CN. 
 
Figure S35. 13C NMR (101 MHz) spectra of 3c in CD3CN.  
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Figure S36. 1H NMR (500 MHz) spectra of 4a in CDCl3. 
 
Figure S37. 13C NMR (101 MHz) spectra of 4a in CDCl3.  
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Figure S38. 1H NMR (400 MHz) spectra of 4b in MeOD. 
 
Figure S39. 13C NMR (101 MHz) spectra of 4b in MeOD.  
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Figure S40. 1H NMR (400 MHz) spectra of 16 in MeOD. 
 
Figure S41. 13C NMR (101 MHz) spectra of 16 in MeOD.  
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Figure S42. 1H NMR (400 MHz) spectra of 10 in MeOD. 
 
Figure S43. 13C NMR (101 MHz) spectra of 10 in MeOD.  
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Figure S44. 1H NMR (400 MHz) spectra of 17 in MeOD. 
 
Figure S45. 13C NMR (101 MHz) spectra of 17 in MeOD.  
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Figure S46. 1H NMR (400 MHz) spectra of 11 in MeOD. 
 
Figure S47. 13C NMR (101 MHz) spectra of 11 in MeOD.  
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Figure S48. 1H NMR (500 MHz) spectra of 12 in MeOD. 
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Figure S49. 2D NOESY NMR spectrum of 2a (500 MHz in CD3CN). 
 
Figure S50. 2D NOESY NMR spectrum of 3a (500 MHz in CD3CN).
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Figure S51. HMBC spectrum of 2a (600 MHz in CD3CN). 
 
Figure S52. HMQC spectrum of 2a (600 MHz in CD3CN).  
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Figure S53. HMBC spectrum of 3a (600 MHz in CD3CN). 
 
Figure S54. HMQC spectrum of 3a (600 MHz in CD3CN).  
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Figure S55. 2D NOESY NMR spectrum of 2c (400 MHz in CD3CN). 
 
Figure S56. 2D NOESY NMR spectrum of 3c (400 MHz in CD3CN). 
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Figure S57. 2D NOESY NMR spectrum of 2d (400 MHz in CD3CN). 
 
Figure S58. 2D NOESY NMR spectrum of 2d after irradiation (400 MHz in CD3CN). 
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Figure S59. 2D NOESY NMR spectrum of 2e (400 MHz in CD3CN). 
 
Figure S60. 2D NOESY NMR spectrum of 2e after irradiation (400 MHz in CD3CN).
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